Michael Newton is a Global Clinical Program Lead in Late Development Oncology R&D at AstraZeneca, where they oversee the clinical team responsible for the design and execution of global immunotherapy trials for unresectable NSCLC. With over 15 years of experience as a clinical oncology pharmacist, Michael has also worked as an Associate Professor and PGY-2 Residency Director at West Virginia University. They have contributed to the advancement of oncology through protocol development, medical monitoring, and mentorship of students across pharmacy and medical disciplines. Michael is board certified in oncology pharmacy and has expertise in various hematology and oncology disease states.
This person is not in any teams
This person is not in any offices